Richard Benarous

Cytomics Pharmaceuticals is a biopharmaceutical company dedicated to discovering and developing drugs that control the degradation of proteins, to treat major human diseases. The company was founded in April 2000 in collaboration with Dominique Thomas (Research Director at the Center for Molecular Genetics of the CNRS) and Richard Benarous (Director of the Department for Infectious Diseases 'at the Cochin Institute of Molecular Genetics), both specialists recognized by the ubiquitin-proteasome protein degradation.

Cytomics Pharmaceuticals is a biopharmaceutical company dedicated to discovering and developing drugs that control the degradation of proteins, to treat major human diseases. The company was founded in April 2000 in collaboration with Dominique Thomas (Research Director at the Center for Molecular Genetics of the CNRS) and Richard Benarous (Director of the Department for Infectious Diseases 'at the Cochin Institute of Molecular Genetics), both specialists recognized by the ubiquitin-proteasome protein degradation.

Cytomics Pharmaceuticals is a biopharmaceutical company dedicated to discovering and developing drugs that control the degradation of proteins, to treat major human diseases. The company was founded in April 2000 in collaboration with Dominique Thomas (Research Director at the Center for Molecular Genetics of the CNRS) and Richard Benarous (Director of the Department for Infectious Diseases 'at the Cochin Institute of Molecular Genetics), both specialists recognized by the ubiquitin-proteasome protein degradation.

CellVir SAS develops anti-retrovirals based on novel therapeutics. Its research is focused on HIV disease. The company was founded by Richard Benarous, Richard Platford, Armand Frydman, E. Thomas Bader, and Jean Deregnaucourt on March 20, 2006 and is headquartered in Evry, France.

CellVir SAS develops anti-retrovirals based on novel therapeutics. Its research is focused on HIV disease. The company was founded by Richard Benarous, Richard Platford, Armand Frydman, E. Thomas Bader, and Jean Deregnaucourt on March 20, 2006 and is headquartered in Evry, France.

CellVir SAS develops anti-retrovirals based on novel therapeutics. Its research is focused on HIV disease. The company was founded by Richard Benarous, Richard Platford, Armand Frydman, E. Thomas Bader, and Jean Deregnaucourt on March 20, 2006 and is headquartered in Evry, France.

CellVir SAS develops anti-retrovirals based on novel therapeutics. Its research is focused on HIV disease. The company was founded by Richard Benarous, Richard Platford, Armand Frydman, E. Thomas Bader, and Jean Deregnaucourt on March 20, 2006 and is headquartered in Evry, France.

Cytomics Pharmaceuticals is a biopharmaceutical company dedicated to discovering and developing drugs that control the degradation of proteins, to treat major human diseases. The company was founded in April 2000 in collaboration with Dominique Thomas (Research Director at the Center for Molecular Genetics of the CNRS) and Richard Benarous (Director of the Department for Infectious Diseases 'at the Cochin Institute of Molecular Genetics), both specialists recognized by the ubiquitin-proteasome protein degradation.

CellVir SAS develops anti-retrovirals based on novel therapeutics. Its research is focused on HIV disease. The company was founded by Richard Benarous, Richard Platford, Armand Frydman, E. Thomas Bader, and Jean Deregnaucourt on March 20, 2006 and is headquartered in Evry, France.

Cytomics Pharmaceuticals is a biopharmaceutical company dedicated to discovering and developing drugs that control the degradation of proteins, to treat major human diseases. The company was founded in April 2000 in collaboration with Dominique Thomas (Research Director at the Center for Molecular Genetics of the CNRS) and Richard Benarous (Director of the Department for Infectious Diseases 'at the Cochin Institute of Molecular Genetics), both specialists recognized by the ubiquitin-proteasome protein degradation.

Cytomics Pharmaceuticals is a biopharmaceutical company dedicated to discovering and developing drugs that control the degradation of proteins, to treat major human diseases. The company was founded in April 2000 in collaboration with Dominique Thomas (Research Director at the Center for Molecular Genetics of the CNRS) and Richard Benarous (Director of the Department for Infectious Diseases 'at the Cochin Institute of Molecular Genetics), both specialists recognized by the ubiquitin-proteasome protein degradation.

CellVir SAS develops anti-retrovirals based on novel therapeutics. Its research is focused on HIV disease. The company was founded by Richard Benarous, Richard Platford, Armand Frydman, E. Thomas Bader, and Jean Deregnaucourt on March 20, 2006 and is headquartered in Evry, France.